No matter how the market flourishes or how promising a technology’s outlook, there’s still one thing that can bring even the most high-flying genomics execs to their knees. It’s the US FDA, headed up by Bernard Schwetz, acting principal deputy commissioner. His years of toxicology research experience have prepared him for what may be the coming onslaught of genomics-based drugs. He recently agreed to an e-mail interview with GT’s Meredith Salisbury.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.